Novo Nordisk launches the Wegovy pill in Germany, its first European market

Novo Nordisk started selling the Wegovy pill in German pharmacies on September 1, 2026, making Germany the first of the European Union's 27 member states to get the oral version of semaglutide, a company spokesperson told Reuters ^[1][2]. The launch follows the European Commission's marketing authorization on July 15, 2026, which cleared once-daily oral semaglutide 25 mg across the bloc after a positive opinion from the European Medicines Agency's CHMP in May ^[1][3].

Novo told Reuters that German prices will vary by dose and will be comparable to the Wegovy injector pen, which currently carries pharmacy retail prices of roughly €170 to €280 ^[1]. Euronews reported the same range for the tablet ^[2]. The medicine is prescription-only in Germany ^[2]. Whether German statutory health insurers will pay for the tablet is not addressed in the launch coverage — price and reimbursement stay national decisions even after an EU-wide approval ^[3].

One detail separates the tablet from the pen: in the EU, Wegovy pens are authorized for adults and adolescents from age 12, while the tablets are for adults only ^[2][3]. The EU label covers adults with obesity (BMI of at least 30) or overweight (BMI of at least 27) plus at least one weight-related condition, as an add-on to diet and activity ^[3]. EMA's public overview says the tablet is taken once a day on an empty stomach after at least eight hours of fasting, with a 30-minute wait before eating, drinking or taking other oral medicines, and the dose is stepped up over 16 weeks to reduce gut side effects ^[3].

The weight-loss numbers don't all match

Different official documents cite different figures, and it is worth keeping them separate. Euronews, citing the OASIS-4 study that underpinned the EU approval, reported average weight loss of about 13.6% among 205 participants taking the tablet versus 102 on placebo over 64 weeks; the injection produced about 19% average loss, though over a longer 72-week period ^[2]. EMA's overview describes a 307-person tablet study showing about 14% mean weight loss at 64 weeks versus about 2% on placebo, with roughly 76% of tablet users losing at least 5% of body weight compared with 31% on placebo ^[3]. Novo's own July 15 press release cited about 17% mean weight loss from OASIS data ^[3]. These are separate write-ups, not one pooled result ^[3].

Side effects mirror the injection. Gastrointestinal complaints including nausea and diarrhea are common, and pancreatitis can occur ^[2]. EMA lists headache, nausea, vomiting, diarrhea, constipation and abdominal pain as effects that may affect more than 1 in 10 people ^[3].

Why it matters for patients

For US readers, the German launch is mainly a pricing and competitive signal rather than a change in access. The Wegovy pill was already launched earlier in 2026 in the US, Britain and the United Arab Emirates ^[1]. But a German retail range of €170 to €280 per month gives a concrete number to compare against US cash-pay and insurance costs, and it shows Novo is pricing the tablet in line with the pen rather than below it ^[1][2].

The adults-only limit on the tablet in the EU is a reminder that pill and injection versions of the same molecule can carry different age labels ^[2][3]. Coverage here does not describe the US label's age terms, so that is not something this launch settles.

Competition is the other thread. Eli Lilly's oral GLP-1, Foundayo (orforglipron), was approved and launched in the US in April 2026, went on sale in the UK in late August, and is under regulatory review in more than 40 markets, with Lilly expecting a rollout across all major markets in 2027 ^[1]. Novo CEO Mike Doustdar said in August that the Wegovy pill had captured about 90% of the oral obesity market despite Lilly's entry ^[1]. Novo has said pills could account for more than a third of GLP-1 use by 2030 ^[1], in a market analysts value at more than $100 billion a year by then ^[1][2].

What happens next

Novo holds its capital markets day on September 21, 2026, where investors will look for detail on the oral rollout ^[1][3]. The company said in July it planned more country launches in the second half of 2026 but has not named the next EU market after Germany ^[3]. No EU-wide sales figures for the tablet have been published yet ^[3].